Hyderabad-based MSN Group has announced the launch of the world’s first generic Palbociclib Tablets, 75mg, 100mg and 125mg for Advanced Breast Cancer Therapy under the brand name PALBOREST.

While there are few other companies launched/set to launch Palbociclib in capsule dosage form, MSN laboratories took the lead in developing the drug in tablet formulation which is in line with the innovator Palbace tablets.

Priced at Rs 257.14 per tablet for 125mg, Rs 233.28 per tablet for 100mg, Rs 214.29 per tablet for 75mg respectively, PALBOREST is more affordable & bioequivalent to innovator tablet.

The tablet dosage form offers distinct advantage over capsule dosage form as they can be taken with or without food. These tablets can be co- administered with proton pump inhibitors (PPIs) or antacids. The tablet formulation does not contain lactose (dairy) or gelatin, which also contributes to the efficacy of the drug.

Palborest comes in a patient compliant pack of 3 strips of 7 tablets each to meet the recommended 3-weeks on, 1-week off treatment schedule.

Palbociclib is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and Central Drugs Standard Control Organisation (CDSCO) in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor negative locally advanced or metastatic breast cancer.